Log In
Print
BCIQ
Print
Print this Print this
 

AVA-101

  Manage Alerts
Collapse Summary General Information
Company Avalanche Biotechnologies Inc.
DescriptionAdeno-associated virus (AAV) vector-based therapy that delivers soluble VEGF receptor 1 (sFLT1; sVEGFR-1), a VEGF inhibitor
Molecular Target Vascular endothelial growth factor (VEGF)
Mechanism of ActionGene therapy
Therapeutic ModalityGene therapy: Viral vector: Adeno-associated virus (AAV)

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

$640.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today